Literature DB >> 23096166

PET/CT of cancer patients: part 1, pancreatic neoplasms.

Elizabeth H Dibble1, Dimitrios Karantanis, Gustavo Mercier, Patrick J Peller, Lisa A Kachnic, Rathan M Subramaniam.   

Abstract

OBJECTIVE: Pancreatic cancer continues to have a poor prognosis despite impressive improvements in the outcomes of many other types of cancer, often because most pancreatic neoplasms are found to be unresectable at diagnosis. The purpose of this review is to provide an overview of pancreatic cancer and the role of modern imaging in its diagnosis and management with an emphasis on (18)F-FDG PET/CT fusion imaging.
CONCLUSION: Multimodality imaging is critical in the diagnosis and management of pancreatic cancer. PET/CT is increasingly viewed as a useful, accurate, and cost-effective modality in diagnosing and managing pancreatic cancer, but further studies are warranted. Early data suggest that contrast-enhanced PET/CT performed with modern PET/CT scanners yields high-resolution anatomic information for surgical and radiotherapeutic planning and functional information for whole-body staging in the care of patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096166     DOI: 10.2214/AJR.11.8182

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  23 in total

Review 1.  Diagnostic evaluation of solid pancreatic masses.

Authors:  Jeffrey L Tokar; Rohit Walia
Journal:  Curr Gastroenterol Rep       Date:  2013-10

Review 2.  Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET.

Authors:  Siva P Raman; Yifei Chen; Elliot K Fishman
Journal:  J Gastrointest Oncol       Date:  2015-04

3.  Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-20       Impact factor: 9.236

Review 4.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 5.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 6.  Current status and progress of pancreatic cancer in China.

Authors:  Quan-Jun Lin; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

7.  Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma.

Authors:  Yukako Ichimiya; Krishna Alluri; Charles Marcus; Simon Best; Christine H Chung; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 8.  Pancreatic cancer: diagnosis and treatments.

Authors:  Hong-Yu Li; Zhong-Min Cui; Jiang Chen; Xiao-Zhong Guo; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-02-14

9.  Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis.

Authors:  Oliver Strobel; Markus W Büchler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-12       Impact factor: 46.802

10.  [Hybrid imaging in diagnostics and therapy of chronic myocardial ischemia. Clinical value].

Authors:  R Dörr; C T Kadalie; W G Franke; M Gutberlet
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.